Table 7. Review of studies about dyslipidemia in older people.
| Studies | Quality assessment | Summary of findings | Quality | |||||||||
| Ref | N | Study design | Limitations | Inconsistency | Indirectness | Imprecision | Publication bias | Relative effect estimates | Absolute effect estimates | |||
| CI: confidence interval; CS: Cohort study; CV: cardiovascular; CVR: cardiovascular risk; DM: patients with diabetes mellitus; HR: Hazard ratio; LDL: low density lipoprotein; NO-DM: Non-diabetic patients; RCT: random clinical trial; Ref: bibliography reference; RR: relative risk; SR: systematic review; U: undetected; UV: unavailable; Quality: quality assessed according to GRADE methodology. | ||||||||||||
| Which is the usefulness of statins for the prevention of cardiovascular disease in the elderly on overall mortality? | ||||||||||||
| 107 | 21 435 | SR | U | U | U | U | U | RR 0.94 | UV | High | ||
| 108 | 4 802 (NO-DM 75-84 years) 743 (NO-DM > 85 years) 1 756 (DM 75-84 years) 201 (DM > 85 years) |
CS | U | U | UV | U | U | RR 0.98 (NO-DM 75-84 years) RR 0.97 (NO-DM > 8 years) RR 0.84 (DM 75-8 years) RR 1.05 (DM> 85 years) |
UV | High | ||
| Which is the usefulness of statins for the prevention of cardiovascular mortality in the elderly? | ||||||||||||
| 107 | 13 914 | SR | U | U | U | U | U | RR 0.90 | UV | High | ||
| Which is the usefulness of statins for the prevention of acute myocardial infarction in the elderly? | ||||||||||||
| 107 | 15 929 | SR | U | U | U | U | U | RR 0.60 | UV | High | ||
| Which is the usefulness of statins for the prevention of stroke in the elderly? | ||||||||||||
| 107 | 16 322 | SR | U | U | U | U | U | RR 0.76 | UV | High | ||
| Which is the usefulness of statins for the prevention of atherosclerotic cardiovascular disease in the elderly? | ||||||||||||
| 107 | 11 556 | SR | U | U | U | U | U | RR 0.89 | UV | High | ||
| Which is the usefulness of statins for the prevention of cancer in the elderly? | ||||||||||||
| 108 | 4 802 (NO-DM 75-84years) 743 (NO-DM > 85years) 1 756 (DM 75-84 years) 201 (DM > 85 years) |
CS | U | U | UV | U | U | RR 0.94 (NO-DM 75-84 years) RR 0.93 (NO-DM > 85 years) RR 0.76 (DM 75-84 years) RR 0.82 (DM > 85 years) |
UV | High | ||
| Which is the usefulness of statins for the prevention of cardiovascular risk in the elderly? | ||||||||||||
| 109 | 186 854 TOTAL (756 with CV treatment/ 295 without CV treatment) |
SR | U | U | U | U | U | RR 0.87 (0.77–0.99) (total) RR 0.85 (0.73–0.98) (with CV treatment) RR 0.92 (0.73–1.16) (without CV treatment) |
UV | High | ||
| 110 | 21 492 | SR RCT | U | U | U | U | U | RR 0.74 (95% CI. 0.61–0.89) | UV | High | ||
| 111 | UV | CS | U | U | UV | U | U | NO CVR in control LDL group (≥ 75 years) | UV | High | ||
| 112 | UV | CS | U | UV | UV | U | U | Lower CVR in control LDL group |
UV | High | ||
| IS IT BETTER THE USE OF PRAVASTINA vs USUAL PRACTICE FOR THE PREVENTION OF THE CARDIOVASCULAR RISK IN THE ELDERLY? | ||||||||||||
| 113 | 1 428 with treatment (>75 years) |
RCT | U | UV | U | U | U | HR 0.80 (IC 95%. 0.70-0.90) | 8.70% | High | ||
| 114 | 1 716 with treatment | RCT | U | UV | UV | U | U | HR 0.75 | UV | Low | ||
| 115 | 4 819 | CS | U | U | UV | U | U | UV | UV | High | ||